Myrexis, Inc. (MYRX)
-OTC Markets 0.07 May 17, 2:20PM EDT|Pre-Market
:
2.96 
0.02 (0.68%) 4:00PM EST - Nasdaq Real Time Price
| Prev Close: | 0.07 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.00 |
|---|
| Beta: | 1.03 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.06 - 3.02 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 379,525 |
|---|
| Market Cap: | 2.41M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.58 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MYREXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- MYREXIS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles of Inc.EDGAR Online(Mon, Apr 29)
- MYREXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other EventsEDGAR Online(Thu, Apr 18)
- MYREXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,EDGAR Online(Tue, Mar 5)
- MYREXIS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Thu, Feb 28)
- MYREXIS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Wed, Feb 20)
- MYREXIS, INC. FinancialsEDGAR Online Financials(Thu, Feb 14)
- MYREXIS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and ExhibitsEDGAR Online(Fri, Feb 8)
- MYREXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, Feb 8)
- MYREXIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TraEDGAR Online(Mon, Jan 28)
- Healthcare Recap: Earnings, Drug Trials, and Liquidationat Wall St. Cheat Sheet(Wed, Jan 23)
- MYREXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal OfficeEDGAR Online(Fri, Dec 21)
- Monday Sector Leaders: Biotechnology, Non-Precious Metals & Non-Metallic Mining Stocksat Forbes(Mon, Nov 12)
- Myrexis and Gilead Sciences Among Most Active Stocks in Nasdaq Pre-Marketat Minyanville(Mon, Nov 12)
- Isis Optimistic on Pipeline, Myrexis Dissolves Itself: Healthcare Business Recapat Wall St. Cheat Sheet(Sat, Nov 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | 19-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Jun-12)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-11)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Myrexis, Inc., a biopharmaceutical company, focuses on identifying, evaluating, and acquiring commercial-stage biopharmaceutical assets. The company intends to acquire one or more life sciences assets.
View More